Regenerative Medicine

Regeneus and Kyocera ink lucrative deal to commercialise Progenza in $3.5 billion dollar market | 8/11/2020

Japan is an important market for clinical stage regenerative medicine company, Regeneus Ltd ( ASX:RGS ), which has just negotiated a license agreement with Kyocera Corporation (Kyocera, TYO:6971) to develop and commercialise Progenza for Knee Osteoarthritis (Progenza OA) in Japan. This provides Kyocera with an exclusive licence in Japan to develop and commercialise Regeneus’ lead mesenchymal stem cell (MSC) and secretome technology Progenza, for the treatment of Knee Osteoarthritis (Knee …

AVITA MED LTD/S (NASDAQ:RCEL) Downgraded to “Hold” at Zacks Investment Research | 8/10/2020

… Research downgraded shares of AVITA MED LTD/S (NASDAQ:RCEL) from a buy rating to a hold rating in a report published on Friday, Zacks.com reports. According to Zacks, “AVITA Therapeutics, Inc. is a regenerative medicine company with a technology platform to address unmet medical needs in burns, chronic wounds and aesthetics indications. AVITA Therapeutics Inc., formerly known as AVITA Medical Limited, is based in Valencia, United States. “ Get AVITA …

Follow Regenerative Medicine:    

Global Cell and Gene Therapy Market, Forecast to 2025 by Product, Disease, End-user and Region - COVID-19 Updated | PR Newswire | 8/10/2020

… therapy market by revenue is expected to grow at a CAGR of over 30.9% during the period 2019-2025 The global cell and gene therapy market is one of the fastest-growing segments in the regenerative medicine market. The market is expected to grow at a faster pace during the forecast period. The demand can be attributed to the growing prevalence of several chronic diseases such as cancer, cartilage related problems …

Mallinckrodt Announces U.S. FDA Filing Acceptance of Biologics License Application for StrataGraft® Regenerative Skin Tissue for Treatment of Adults with Deep Partial-thickness Thermal Burns | PR Newswire | 8/10/2020

… completion of the BLA rolling submission was announced on June 9, 2020 . The FDA granted StrataGraft skin tissue orphan drug designation, and it was among the first products designated by the Agency as a Regenerative Medicine Advanced Therapy (RMAT) under the provisions of the 21st Century Cures Act. About StrataGraft StrataGraft regenerative skin tissue is an investigational treatment being developed to reduce autograft in patients with severe thermal burns. An …

Pluristem Expands its COVID-19 Program to Europe, Receives PEI Clearance to Commence Phase II Study in Germany Nasdaq:PSTI | Globe Newswire | 8/10/2020

HAIFA, Israel, Aug. 10, Pluristem Therapeutics Inc. (Nasdaq: PSTI ) (TASE: PSTI ) , a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that Germany’s health regulatory agency, the Paul Ehrlich Institute (PEI), has cleared the Company’s Phase II clinical protocol for its study titled, “A Randomized, Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for …

Cord Blood Registry (CBR®) By Generate Life Sciences Partners With NantKwest To Develop COVID-19 Treatment | PR Newswire | 8/10/2020

… research-donated umbilical cord tissue-derived mesenchymal stem cells (MSCs) to NantKwest for efficient and robust expansion utilizing their proprietary modular, closed bioreactor system from NantKwest affiliate ImmunityBio, Inc. Anticipating the emerging relevance of regenerative medicine , CBR was the first private stem cell bank to offer families the option of umbilical cord tissue cryopreservation and has developed a novel method to efficiently create a pure MSC cellular product from cryopreserved …

BrainStorm to Present at the 40th Annual Canaccord Genuity Growth Conference | PR Newswire | 8/10/2020

… ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 …

I truly believe that X39 will have a major impact | 8/10/2020

… below. One of his inventions, the Double Helix Conductor, received a research grant from Scientific Foundation Ireland and was evaluated with multiple research studies at the National University of Ireland Galway (NUIG) and the Regenerative Medicine Institute (REMEDI). It was uncovered in this research program that the use of this device, which produces a novel blend of electromagnetic and non-electromagnetic fields, could produce improvements in the speed of wound …

Associate Professor/Professor of 3D Models in Health & Disease | 8/10/2020

… is a new appointment for an academic with an international reputation, a strong track record of extensive publications in high quality peer-reviewed scientific journals, and a track record of successful funded research in regenerative medicine and specifically in laboratory models of tissues for testing and functional implantation, reducing the use of animal experimentation. The appointment will be key to the cross-disciplinary campus-wide initiative in regenerative medicine , also …

Humanigen Expands Phase III Study of Lenzilumab in COVID-19 to Brazil | Business Wire | 8/10/2020

… clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine /gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has …

Cord Blood Registry (CBR�) By Generate Life Sciences Partners With NantKwest To Develop COVID-19 Treatment - GuruFocus.com | 8/10/2020

… for efficient and robust expansion utilizing their proprietary modular, closed bioreactor system from NantKwest affiliate ImmunityBio, Inc. 3 Warning Signs with NAS:NK. NAS:NK NAS:NK NAS:NK Anticipating the emerging relevance of regenerative medicine , CBR was the first private stem cell bank to offer families the option of umbilical cord tissue cryopreservation and has developed a novel method to efficiently create a pure MSC cellular product from cryopreserved …

Mallinckrodt Announces U.S. FDA Filing Acceptance of Biologics License Application for StrataGraft(R) Regenerative Skin Tissue for Treatment of Adults with Deep Partial-thickness Thermal Burns | 8/10/2020

Biopharmaceuticals Regenerative Medicine FDA Mallinckrodt Announces U.S. FDA Filing Acceptance of Biologics License Application for StrataGraft(R) Regenerative Skin Tissue for Treatment of Adults with Deep Partial-thickness Thermal Burns StrataGraft® Skin Tissue, If Approved, Could Reduce or Eliminate the Need for Autografting of Healthy Skin to Treat Burn Wounds STAINES-UPON-THAMES, United Kingdom, Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food and …

Crwe World | Athersys Reports Second Quarter 2020 Results | 8/10/2020

… Advanced our partnering discussions with companies interested in MultiStem commercialization rights in Europe and other regions; Participated in several events throughout the second quarter, including the Bank of America Healthcare Conference, the Alliance for Regenerative Medicine webinar, the International Society of Cell & Gene Therapy, and a CEO round table at LifeScience Leader, and participated in several media interviews and podcasts; Continued to advance the enrollment of the MASTERS-2 ischemic …

Wyatt Law Firm, Carabin Shaw Partner To Help COVID-19 Patients | PR Newswire | 8/10/2020

… recovers and distributes donated human tissue for transplant. STBTC has a 45-year history serving the South Texas community. It is part of the BioBridge Global family of nonprofit organizations, which offers services in regenerative medicine and research including blood banking and resource management; cellular therapy; umbilical cord blood collection and storage; donated human tissue recovery and distribution for transplant; and testing of blood and plasma products to help patients …

Bioprinting: Creating pinhead replicas of human organs to fight COVID-19 and other ailments | 8/10/2020

Anthony Atala, the director of the Wake Forest Institute for Regenerative Medicine , and his team are… creating tiny replicas of human organs — some as small as a pinhead — to test drugs to fight Covid-19. The team is constructing miniature lungs and colons — two organs particularly affected by the coronavirus — then sending them overnight by courier for testing at a biosafety lab at George Mason University in Fairfax, Va. … Dr …

AVITA MED LTD/S (NASDAQ:RCEL) Stock Rating Upgraded by Zacks Investment Research - TheOlympiaReport | 8/9/2020

… has a $26.00 price target on the stock. Zacks Investment Research ‘s price target would suggest a potential upside of 7.88% from the company’s current price. According to Zacks, “AVITA Therapeutics, Inc. is a regenerative medicine company with a technology platform to address unmet medical needs in burns, chronic wounds and aesthetics indications. AVITA Therapeutics Inc., formerly known as AVITA Medical Limited, is based in Valencia, United States. “ Get AVITA …

Zacks Investment Research Downgrades AVITA MED LTD/S (NASDAQ:RCEL) to Hold | 8/9/2020

… S (NASDAQ:RCEL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday, Zacks.com reports. According to Zacks, “AVITA Therapeutics, Inc. is a regenerative medicine company with a technology platform to address unmet medical needs in burns, chronic wounds and aesthetics indications. AVITA Therapeutics Inc., formerly known as AVITA Medical Limited, is based in Valencia, United States. “ Get AVITA …

AVITA MED LTD/S (NASDAQ:RCEL) Cut to Hold at Zacks Investment Research | 8/9/2020

… LTD/S (NASDAQ:RCEL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday, Zacks.com reports. According to Zacks, “AVITA Therapeutics, Inc. is a regenerative medicine company with a technology platform to address unmet medical needs in burns, chronic wounds and aesthetics indications. AVITA Therapeutics Inc., formerly known as AVITA Medical Limited, is based in Valencia, United States. “ Get AVITA …

AVITA MED LTD/S (NASDAQ:RCEL) Stock Rating Lowered by Zacks Investment Research | Daily Political | 8/9/2020

AVITA MED LTD/S (NASDAQ:RCEL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Friday, Zacks.com reports. According to Zacks, “AVITA Therapeutics, Inc. is a regenerative medicine company with a technology platform to address unmet medical needs in burns, chronic wounds and aesthetics indications. AVITA Therapeutics Inc., formerly known as AVITA Medical Limited, is based in Valencia, United …

Science Saturday: Seeking a regenerative therapy for chronic dry mouth | Mayo Clinic | 8/8/2020

… the decrease in saliva that comes from xerostomia. Besides being uncomfortable, chronic dry mouth can lead to difficulties with chewing, tasting, speaking and swallowing. It can also cause tooth decay. Mayo Clinic Center for Regenerative Medicine , Department of Laboratory Medicine and Pathology and Department of Otolaryngology are collaborating on ways to address the unmet needs of these patients. The question investigators are seeking to answer is whether the body’s healing …

Old human cells rejuvenated with stem cell technology, research finds | 8/8/2020

… as induced pluripotent stem cells, or iPS cells. Induced pluripotent stem cells can become nearly any type of cell in the body, regardless of the cell from which they originated. They’ve become important in regenerative medicine and drug discovery. The study found that inducing old human cells in a lab dish to briefly express these proteins rewinds many of the molecular hallmarks of aging and renders the treated cells nearly …

COVID FBI | 8/8/2020

… class if we knew Pacific Islanders that might be interested; they said they would waive the requirement for a bachelors degree. There was so much to cover we did not make it to the regenerative medicine information. For the morning portion of class, Dr. Cherie Chu was our guest lecturer. She is a pharmacologist and assistant professor at UH Hilo. We learned about the pros & cons of existing drugs that …

Training neural circuits early in development improves response, study finds | 8/7/2020

… if we stimulate it when it’s still like a puppy, we can get a better response to the training than if it were already mature.” Improved neural training has many applications in bioengineering and regenerative medicine . For example, the Illinois team hopes to use trained neural circuits to control the movement and behavior of miniature bio-hybrid machines. The types of improvements yielded by early training could give the machines …

Grant Funds Placenta Stem Cell Trial Sites for Covid-19 | 8/7/2020

… three more sites in California. The new sites for the trial conducted by Celularity Inc. , a company based in Florham Park, New Jersey, are funded by a $750,000 grant from the California Institute for Regenerative Medicine , or CIRM. Celularity develops treatments for cancer, infectious diseases, and other disorders with blood-forming stem cells derived from donated human placenta tissue. The company’s technology extracts natural killer cells, with target cell-killing …

Developmental excitation-inhibition imbalance underlying psychoses revealed by single-cell analyses of discordant twins-derived cerebral organoids | 8/7/2020

… we treated the SNL76/7 cells with 12.4 μg/ml Mitomycin C (Sigma) for 2.25 h. The human iPSC line 409B2 was provided by the RIKEN BRC (Ibaraki, Japan) through the Project for Realization of Regenerative Medicine and the National Bio-Resource Project of the MEXT, Japan [ 15 ]. Human dermal fibroblasts (HDFs) (RIKEN BRC) were maintained in MEM α (Thermo Fisher Scientific) supplemented with 10% FBS. To quantify the exogenous expression …

Gene Therapy

IPO Update: Poseida Therapeutics Proposes $150 Million IPO | Seeking Alpha | 7/7/2020

… and president of Transposagen, a receptor editing firm. Below is a brief summary movie of Poseida’s approach: Source: Alliance for Regenerative Medicine The company’s lead writer is P-BCMA-101, a CAR-T cure for … biopharma companies throughout the world. In addition, companies are developing gene therapy technologies and they include large pharma and little biopharma companies. Management says its patent estate supplies it with’significant intellectual property security.’ Financial Status …

Digital Health

The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A… | National Institutes of Health | 7/6/2020

… Sweden; Molecular & Clinical Sciences Research Institute, St George University London, UK; Brunel University, Middlesex, UK. 6 Institute of Cardiology and Regenerative Medicine, Faculty of Medicine, University of Latvia, Riga, Latvia; Pauls Stradins Clinical University Hospital … Pharmacognosy, University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Digital Health and Patient Safety, Medical University of Vienna, Vienna, Austria; Institute of Neurobiology, Bulgarian Academy of Sciences, Sofia, Bulgaria. 12 Institute of Public Health …

Patient Safety

The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A… | National Institutes of Health | 7/6/2020

… Sweden; Molecular & Clinical Sciences Research Institute, St George University London, UK; Brunel University, Middlesex, UK. 6 Institute of Cardiology and Regenerative Medicine, Faculty of Medicine, University of Latvia, Riga, Latvia; Pauls Stradins Clinical University Hospital … Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Digital Health and Patient Safety, Medical University of Vienna, Vienna, Austria; Institute of Neurobiology, Bulgarian Academy of Sciences, Sofia, Bulgaria. 12 Institute of Public Health and Clinical Medicine …

Centers for Medicare and Medicaid Services

BioStem Technologies, Inc. Announces Submission of Applications for Q-Codes from the Centers for Medicare and Medicaid Services (CMS) | Globe Newswire | 7/2/2020

… for regenerative therapies, today announced the submission of applications for three of its dehydrated placental membrane allograft products to the Centers for Medicare and Medicaid Services (CMS), in process to be granted Q-Codes. Q … life sciences corporation, providing innovative technologies with a concentration in Regenerative Medicine. The company’s mission is to discover, develop and produce the most effective Regenerative Medicine products in the world. BioStem Technologies offers a comprehensive …

Medical Education

Immunotherapy shows potential in treating lung fibrosis | News Center | Stanford Medicine | 6/24/2020

… of researchers led by assistant professor of pathology Gerlinde Wernig , MD, at the Stanford Institute for Stem Cell Biology and Regenerative Medicine , has shown that scar tissue cells called fibroblasts are able to proliferate by … and Regenerative Medicine. Email him at . Stanford Medicine integrates research, medical education and health care at its three institutions - Stanford University School of Medicine , Stanford Health Care (formerly Stanford Hospital & Clinics) , and Lucile Packard Children’s …

CAR-T

Gene editing turns immune cells into more potent cancer killers | FierceBiotech | 6/15/2020

… by cytokines such as IL-15, said senior author Dan Kaufman, M.D., Ph.D., professor of medicine in the Division of Regenerative Medicine at the University of California, San Diego (UCSD), in a statement . The researchers … with the FDA approvals of Novartis’ Kymriah and Gilead’s Yescarta, CAR-T treatments for some forms of blood cancer. But there is growing enthusiasm in the biopharma industry for NK-cell-based therapies to treat …

Hematology

CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress | Globe Newswire | 6/12/2020

… and highlighted recent progress in the CTX001 development program. These data were presented during an oral presentation at the European Hematology Association (EHA) virtual congress by Dr. Selim Corbacioglu, Professor of Pediatrics and the Chair … progress in this program to date, CTX001 has been granted Regenerative Medicine Advanced Therapy (RMAT) from the U.S. FDA, Orphan Drug Designation from both the FDA and the European Medicines Agency (EMA), and Fast Track …

Clinical Pharmacology

Expression Dynamics of Integrin α2, α3, and αV Upon Osteogenic Differentiation of Human Mesenchymal Stem Cells - PubMed | National Institutes of Health | 6/11/2020

Clinical Pharmacology and Therapeutics, Kyung Hee University School of Medicine, Seoul, 02447, Korea. 3 Department of Nanobiomedical Science, BK21 PLUS NBM Global Research Center for Regenerative Medicine, College of Dentistry, Dankook University, Cheonan, 330-714, Korea. [email protected] 4 Department of Integrative Bioscience and Biotechnology, Institute of Anticancer Medicine Development, Sejong University, 209 Neungdong-ro, Gwangjin-gu, Seoul, 05006, Korea. [email protected] PMID: 32493499 Favorites Abstract Background: The differentiation of human …

NIH

Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required) | National Institutes of Health | 6/4/2020

U.S. Department of Health & Human Services COVID-19 is an emerging, rapidly evolving situation Get the latest public health information from CDC: https://www.coronavirus.gov Get the latest research information from NIH: https://www.nih.gov/coronavirus Get the latest information and resources from NHLBI: https://www.nhlbi.nih.gov/coronavirus Read Less …

CRISPR

Pluristem Joins Forces with CRISPR-IL National Consortium to Advance Development of Cutting-Edge Genome Editing Solutions for Life Science Products | Globe Newswire | 6/3/2020

regenerative medicine company developing a platform of novel biological products, today announced that it was selected as a member of the CRISPR-IL consortium, a group funded by the Israeli Innovation Authority. CRISPR-IL brings together the leading experts in life science and computer science from academia, medicine, and industry, to develop artificial intelligence (AI) based end-to-end genome-editing solutions. These next-generation, multi-species genome editing products …

Clinical Research

Scientists find optimal age of stem cells | Phys Org | 5/27/2020

Biophysicists from the Moscow Institute of Physics and Technology and Vladimirsky Moscow Regional Clinical Research Institute have determined the optimal age of reprogrammed stem cells suitable for restoring heart tissue. It spans the period roughly from day 15 until day 28 of maturation. The research findings were published in Scientific Reports . Induced pluripotent stem cells , or iPSCs, are used in regenerative medicine . Derived from human blood , these cells undergo chemical …

HIPAA

Technomad Selected as Electronic Data Capture Partner for Investigational New Drug Application for COVID-19 | PRWeb | 5/26/2020

… HIPAA-compliant cloud-based electronic data capture (EDC) platform, ChartPad®, was selected by Organicell Regenerative Medicine, Inc for the study of two FDA-approved Emergency Single Patient Compassionate Use trials. The study is taking place at Landmark Hospitals, a state-of-the-art hospital system of six long-term acute care hospitals across the Southeast. Two recovering COVID-19 patients in the ICU setting at Landmark Hospital of Athens, GA …

Big Pharma

The untold story of Moderna as the biotech’s coronavirus vaccine faces a test that could make it one of the most consequential startups of all time (MRNA) | Business Insider | 5/23/2020

… biotech . Then, this year, the coronavirus struck. Moderna lapped the drug industry in crafting a coronavirus vaccine candidate, zooming past Big Pharma competitors that dwarf the company in size and resources. Moderna’s experimental serum was … crafting vaccines, but also attempting to tackle cancer, therapeutics, and regenerative medicine. Moderna has further distanced itself by building a state-of-the-art manufacturing facility, repurposing an old Polaroid plant in Norwood, Massachusetts. Tablets …

Ohio State University

IU Team Pursues Breathtaking Regenerative Medicine Advances | 5/17/2020

IU Team Pursues Breathtaking Regenerative Medicine Advances By Associated Press , Wire Service Content May 17, 2020 By Associated Press , Wire Service Content May 17, 2020, at 12:01 a.m. More By SAM STALL, Indianapolis Business Journal … the nascent field of regenerative medicine, moved his lab from Ohio State University to the Indiana University School of Medicine. He brought along a team of about 30 researchers and $10 million in research grants …

Biotech

Asia-Pacific CAR-T Pipeline Insights 2020 Featuring Over 50 CAR-T Therapy Companies in the Region | Globe Newswire | 5/15/2020

… Pacific CAR-T Pipeline” report has been added to ResearchAndMarkets.com’s offering. The Asia-Pacific CAR-T pipeline features over 50 regenerative medicine companies focusing on CAR-T in Asia. The report derives insights from in … readers a closer look into the pipelines of Nanjing Legend Biotech, CARsgen Therapeutics, JW Therapeutics, AbClon, BiocurePharm, Eutilex, Daiichi Sankyo, Celgene, Otsuka and many more. Key Topics Covered …

Food and Drug Administration

Cellect Biotechnology Announces Positive Data Demonstrating Robust Engraftment Using ApoGraft was Featured in Bone Marrow Transplantation; Primary Data Points Were Submitted to the FDA During Investigational New Drug Approval Process | PR Newswire | 5/11/2020

… published in this paper, was included in the Company’s Investigational New Drug (IND) application, which was approved by the U.S. Food and Drug Administration in late 2019. The Company has received all the necessary approvals … treatments and procedures in a wide variety of applications in regenerative medicine. The Company’s current clinical trial is aimed at bone marrow transplantations in cancer treatment. Forward Looking Statements This press release contains forward-looking …

Clinical Data

jCyte Inc. Enters into Ex-US Licensing and Commercialization Agreement for jCell Therapy with Global Ophthalmology Leader Santen Pharmaceutical | Business Wire | 5/8/2020

… when host photoreceptors can be protected and potentially reactivated. jCell has been developed with support from the California Institute for Regenerative Medicine (CIRM), which has funded previous preclinical development and ongoing clinical studies. In the … jCyte Regenerative Medicine Advanced Therapy (RMAT) designation based on early clinical data, making jCell potentially eligible for BLA priority review. In addition to RMAT, jCell has received Orphan Drug designation from the FDA and the …

CDC

Analysis on New Product Launches in Covid-19 Related Markets-Global Allergy Rhinitis Drugs Market 2020-2024 | Evolving Opportunities with Alcon Inc. and ALK-Abello AS | Technavio | Business Wire | 5/5/2020

… University of Korea. In addition, about 12 million people diagnosed with allergic rhinitis, visited physicians in 2017, according to the CDC. A person suffering from this condition experiences various symptoms including rhinorrhea, sneezing, nasal pruritus … is involved in the development and production of gene therapy, regenerative medicines, and stem cell therapies. The company provides Ryaltris, which is fixed-dose combination nasal spray of an antihistamine and a steroid. This medication …

COVID-19

Pluristem Announces Pricing of Its Registered Direct Offering for Aggregate Proceeds of $15 Million | Globe Newswire | 5/5/2020

HAIFA, Israel, May 05, Pluristem Therapeutics Inc. (Nasdaq: PSTI ) (TASE: PSTI ), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that it has entered into definitive agreements with two … PLX cell therapy in the treatment of complications arising from COVID-19 and other clinical trial activities, investment in capital equipment and other general corporate purposes. The offering is expected to close on or before …

National Institutes of Health

Outlook on the Worldwide Tissue Engineering Industry to 2027 - Growth in the Global Healthcare Market Presents Opportunities | Globe Newswire | 4/24/2020

National Institutes of Health (NIH) funding study in the US, the research studies pertaining to stem cell and regenerative medicines received funding of USD 1.8 billion and USD 1.0 billion, respectively, in 2018.The global tissue engineering market is segmented into material type and application. The tissue engineering market, by material type, is further segmented into synthetic material, biologically derived materials, and others. The biologically derived materials segment held the …

Department of Health and Human Services

Regenerative Therapies Market To surpass US$ 45.9 Bn globally by end of 2027 – Coherent Market Insights | Globe Newswire | 4/22/2020

… regenerative medicine, received US$ 33.3 million contract from the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, to support Cellphire’s next generation platelet-based hemostatic products. Request for Sample PDF copy @ https://www.coherentmarketinsights.com/insight/request-sample/3712 Moreover, increasing waiting list for organ transplant is also expected to aid in growth of the market. For instance, according to the U.S. Government Information on …

Health Research

Orbsen Therapeutics Launches Clinical Trial to Address Leading Cause of Death Among COVID-19 Patients | PRWeb | 4/8/2020

… Wellcome Trust, has been approved by the United Kingdom’s Medical Health Regulatory Agency (MHRA). Also, the UK’s National Institute of Health Research (NIHR) designated the trial as a National Urgent Public Health Study. “While more … of cellular immunotherapy. The company, which spun-out from Ireland’s Regenerative Medicine Institute at the National University of Ireland Galway, has developed proprietary technologies that enables the isolation of a well characterized population of pure …

Burn Care

Mallinckrodt Initiates Rolling Submission of Biologics License Application for StrataGraft® Regenerative Skin Tissue to U.S. Food and Drug Administration | PR Newswire | 4/6/2020

… based on data from the pivotal Phase 3 STRATA2016 clinical trial, previously published as an abstract in the Journal of Burn Care & Research and accepted for presentation at the American Burn Association 52 nd Annual … among the first products designated by the Agency as a Regenerative Medicine Advanced Therapy (RMAT) under the provisions of the 21st Century Cures Act. About StrataGraft StrataGraft regenerative skin tissue is an investigational treatment being …

Rice University

MIT’s Koch Institute wins STAT Madness with technology to see tiny ovarian tumors | 4/6/2020

… tumors deep in the body and unseen by a surgeon’s eyes. The other finalist, from the Texas Heart Institute and Rice University, created fibers from “magical” carbon nanotubes to bridge over scarred heart tissue following … at all. There are other lines of research: One is regenerative medicine, which grows new heart tissue on scaffolds seeded with stem cells and implanted in the heart, and another is genetic engineering, to manipulate …

Mental Health

The Allergan Foundation Donates $2.0 Million to Community Organizations on Front-Line of COVID-19 Response | PR Newswire | 3/30/2020

… of COVID-19 Response - Total 2020 Charitable Grants to Date Approach $13 Million, Including More than $3 million Devoted to Mental Health - - Lifetime Giving Exceeds $100 Million - News provided by Mar 30, 2020, 09:40 ET … developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key …

BrainStorm Cell Therapeutics

BrainStorm Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer’s Disease Program | PR Newswire | 7/8/2020

… 8:15 AM ET News provided by Jul 08, 2020, 05:31 ET Share this article NEW YORK , July 8, 2020 /PRNewswire/ – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI ), a leading developer of adult stem cell therapies for … sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm …

Novartis

IPO Update: Poseida Therapeutics Proposes $150 Million IPO | Seeking Alpha | 7/7/2020

… and president of Transposagen, a receptor editing firm. Below is a brief summary movie of Poseida’s approach: Source: Alliance for Regenerative Medicine The company’s lead writer is P-BCMA-101, a CAR-T cure for … at least $227 million and also include Malin Life Science, Novartis Pharma ( NVS ), and Longitude Venture Partners. Market & Competition Based on a 2020 marketplace research report , the global market for multiple myeloma therapies was valued …

Gilead

Drugmakers are racing to use existing medicines to fight the coronavirus. Here’s what you need to know about the 14 most promising medications being put to the test. | Business Insider | 7/6/2020

… surge in the US. Of the dozens that have been tried, two so far have come out with positive results: Gilead’s antiviral remdesivir and a cheap steroid called dexamethasone . Others, including hydroxychloroquine, Kaletra, and Kevzara … help some COVID-19 patients recover. Mesoblast is an Austalian regenerative medicine company that is now applying an experimental stem cell treatment called remestemcel-L to the pandemic. The company is working with NIH researchers …

Vertex Pharmaceuticals

CRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility | Globe Newswire | 6/25/2020

regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com . CRISPR Therapeutics Forward-Looking …

Medtronic

Outlook on the Worldwide Regenerative Medicine Industry to 2024 - Rising Global Healthcare Expenditure Presents Opportunities | Globe Newswire | 6/22/2020

Dublin, June 22, 2020 (GLOBE NEWSWIRE) – The “Global Regenerative Medicine Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)” report has been added to ResearchAndMarkets.com’s offering. This report provides an in-depth analysis of … North America Europe Asia Pacific ROW Company Coverage: Novartis AG Medtronic Plc Bristol Myers Squibb (Celgene Corporation) Smith+Nephew (Osiris Therapeutics, Inc.) Regenerative medicines emphasise on the regeneration or replacement of tissues, cells or organs …

Celgene Corp

Outlook on the Worldwide Regenerative Medicine Industry to 2024 - Rising Global Healthcare Expenditure Presents Opportunities | Globe Newswire | 6/22/2020

Bristol Myers Squibb (Celgene Corporation) Smith+Nephew (Osiris Therapeutics, Inc.) Regenerative medicines emphasise on the regeneration or replacement of tissues, cells or organs of the human body to cure the problem caused by disease or injury. The treatment fortifies the human cells to heal up or transplant stem cells into the body to regenerate lost tissues or organs or to recover impaired functionality. There are three types of stem cells …

Thermo Fisher Scientific

The Global Cell Isolation/Cell Separation Market is expected to grow from USD 6,356.88 Million in 2019 to USD 14,485.68 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 14.71% | Globe Newswire | 6/19/2020

… Isolation/Cell Separation Market is studied across Biomolecule Isolation, Cancer Research, In Vitro Diagnostics, Stem Cell Research, and Tissue Regeneration & Regenerative Medicine. On the basis of End User, the Cell Isolation/Cell Separation Market is … Ug (Haftungsbeschränkt) & Co. Kg, Stemcell Technologies, Inc., Terumo Bct, and Thermo Fisher Scientific, Isolation/Cell Separation Market Isolation/Cell Separation Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global …

Abbott Laboratories

QualTex Laboratories offers two COVID-19 antibody assays | Globe Newswire | 6/17/2020

… nonprofit BioBridge Global, has been performing the SARS-CoV-2 IgG Antibody ELISA assay since April. A second assay, the Abbott Laboratories Architect Antibody assay, went into full-scale production for a QualTex customer on … subsidiary of BioBridge Global, a nonprofit organization comprising services for regenerative medicine and research to help patients in South Texas, the United States and worldwide. Visit us at QualTexlabs.org . About BioBridge Global: BioBridge Global (BBG …

Illumina

Non-Invasive Prenatal Testing (NIPT) Market Worth $13.14 Billion by 2027, Growing at a CAGR of 17.1% from 2019- Global Opportunity Analysis and Industry Forecasts by Meticulous Research® | Globe Newswire | 6/16/2020

… testing (NIPT), paternity testing, and newborn screening. Technological advancements in the healthcare industry such as wearable healthcare devices, sequencing technologies, regenerative medicine, and genomic technologies, supported by breakthroughs in the field of genome sequencing and … Health formerly known as Premaitha Health plc. (U.K.) partnered with Illumina Inc. (U.S.) to use the Illumina’s sequencing technology for the NIPT test developed by Premaitha. The growth in the overall NIPT market is majorly …

Merck

Gene editing turns immune cells into more potent cancer killers | FierceBiotech | 6/15/2020

… by cytokines such as IL-15, said senior author Dan Kaufman, M.D., Ph.D., professor of medicine in the Division of Regenerative Medicine at the University of California, San Diego (UCSD), in a statement . The researchers … collaboration. Dragonfly also has a $695 million research pact with Merck, which was expanded in March. The potential for NK cells to be developed as off-the-shelf treatments for cancer is a major attraction …

Amgen

Gene editing turns immune cells into more potent cancer killers | FierceBiotech | 6/15/2020

… by cytokines such as IL-15, said senior author Dan Kaufman, M.D., Ph.D., professor of medicine in the Division of Regenerative Medicine at the University of California, San Diego (UCSD), in a statement . The researchers … Last September, Nkarta raised $114 million from the likes of Amgen Ventures and Deerfield Management to advance its pipeline of off-the-shelf NK cell therapies. Its lead candidate, NKX101, targets the cell surface receptor …

Bluebird Bio

New Data Show Near Elimination of Sickle Cell Disease-Related Vaso-Occlusive Crises and Acute Chest Syndrome in Phase 1/2 Clinical Study of bluebird bio’s LentiGlobin™ Gene Therapy for Sickle Cell Disease at 25th EHA Congress | Business Wire | 6/12/2020

CAMBRIDGE, Mass.- bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from its ongoing Phase 1/2 HGB-206 study of investigational LentiGlobin™ gene therapy for adult and adolescent patients with sickle cell disease (SCD) show … treatment of SCD. The U.S. FDA granted orphan drug designation, regenerative medicine advanced therapy (RMAT) designation and rare pediatric disease designation for LentiGlobin for SCD. LentiGlobin for SCD is investigational and has not been approved …

MiMedx

COVID-19 Impact and Recovery Analysis- Regenerative Medicine Market 2020-2024 | Increasing Prevalence of Chronic Diseases to Boost Growth | Technavio | Business Wire | 6/4/2020

LONDON–(BUSINESS WIRE)–Jun 4, 2020– Technavio has been monitoring the regenerative medicine market and it is poised to grow by USD 9.55 billion during 2020-2024, progressing at a CAGR of over 20% during the … Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd., and Zimmer Biomet Holdings Inc. are some of the major market participants …

Integra LifeSciences

COVID-19 Impact and Recovery Analysis- Regenerative Medicine Market 2020-2024 | Increasing Prevalence of Chronic Diseases to Boost Growth | Technavio | Business Wire | 6/4/2020

LONDON–(BUSINESS WIRE)–Jun 4, 2020– Technavio has been monitoring the regenerative medicine market and it is poised to grow by USD 9.55 billion during 2020-2024, progressing at a CAGR of over 20% during the … forecast period. Allergan Plc, Amgen Inc., Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd., and Zimmer Biomet Holdings Inc. are …

Allergan

COVID-19 Impact and Recovery Analysis- Regenerative Medicine Market 2020-2024 | Increasing Prevalence of Chronic Diseases to Boost Growth | Technavio | Business Wire | 6/4/2020

LONDON–(BUSINESS WIRE)–Jun 4, 2020– Technavio has been monitoring the regenerative medicine market and it is poised to grow by USD 9.55 billion during 2020-2024, progressing at a CAGR of over 20% during the … the degree of fragmentation will accelerate during the forecast period. Allergan Plc, Amgen Inc., Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical …

MiMedx Group

COVID-19 Impact and Recovery Analysis- Regenerative Medicine Market 2020-2024 | Increasing Prevalence of Chronic Diseases to Boost Growth | Technavio | Business Wire | 6/4/2020

LONDON–(BUSINESS WIRE)–Jun 4, 2020– Technavio has been monitoring the regenerative medicine market and it is poised to grow by USD 9.55 billion during 2020-2024, progressing at a CAGR of over 20% during the … Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd., and Zimmer Biomet Holdings Inc. are some of the major market participants …

GE Healthcare

Toronto centre solving cell manufacturing challenges to benefit patients and global industry | Globe Newswire | 6/2/2020

CCRM and Cytiva, formerly part of GE Healthcare Life Sciences, renew collaboration agreement for Centre for Advanced Therapeutic Cell Technologies June 02, 2020 06:00 ET Source: Centre for Commercialization of Regenerative Medicine (CCRM) TORONTO and MARLBOROUGH, Mass., June 02, 2020 (GLOBE NEWSWIRE) – With Health Canada and the Food and Drug Administration beginning to approve and reimburse cell and gene therapies in significant numbers, the demand for cell and viral vector …

ImmunoGen

ImmunoGen Appoints Stacy Coen as Senior Vice President and Chief Business Officer - Business Wire | 6/1/2020

ImmunoGen Appoints Stacy Coen as Senior Vice President and Chief Business Officer June 01, 2020 08:00 AM Eastern Daylight Time WALTHAM, Mass.–( BUSINESS WIRE )– ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of … and is a member of MassBio and the Alliance for Regenerative Medicine (ARM). Ms. Coen received a BS in Finance and Economics from the University of Massachusetts and an MBA from the Darden Graduate School …

Genzyme

ImmunoGen Appoints Stacy Coen as Senior Vice President and Chief Business Officer - Business Wire | 6/1/2020

Genzyme Corporation (now known as Sanofi Genzyme), including Vice President, Head of Rare Disease Business Development and Licensing, and Vice President, Global Head of Strategy and Business Development, Multiple Sclerosis, among others. She currently serves on the Board of Trustees of Huntington’s Disease Society of America and is a member of MassBio and the Alliance for Regenerative Medicine (ARM). Ms. Coen received a BS in Finance and Economics from the …

Sanofi Genzyme

ImmunoGen Appoints Stacy Coen as Senior Vice President and Chief Business Officer - Business Wire | 6/1/2020

… Sanofi Genzyme), including Vice President, Head of Rare Disease Business Development and Licensing, and Vice President, Global Head of Strategy and Business Development, Multiple Sclerosis, among others. She currently serves on the Board of Trustees of Huntington’s Disease Society of America and is a member of MassBio and the Alliance for Regenerative Medicine (ARM). Ms. Coen received a BS in Finance and Economics from the University of Massachusetts and an …

Iovance Biotherapeutics

Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program | Globe Newswire | 5/29/2020

… Months of Median Study Follow Up 36.4% Overall Response Rate (ORR) Maintained SAN CARLOS, Calif., May 29, 2020 (GLOBE NEWSWIRE) – Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based … from accelerated FDA review designations, including breakthrough therapy designation or regenerative medicine advanced therapy designation, which may not result in a faster development process or review of the Company’s product candidates (and which may later …

Thermo Fisher

$5.9 Billion Failure Analysis Market Outlook, 2025 - Implications of COVID-19, Trends & Developments, Key Players | PR Newswire | 5/28/2020

… in demand for failure analysis from the electronics & semiconductor industry, technological advancements in microscopes, and rising focus on nanotechnology and regenerative medicine. Energy Dispersive X-Ray Spectroscopy (EDX) technology expected to hold the largest share … microscopy in life sciences and nanotechnology research in this region. Thermo Fisher Scientific, Inc. (US), Hitachi High-Technologies Corporation ( Japan ), Carl Zeiss ( Germany ), JOEL, Ltd. ( Japan ), TESCAN OSRAY HOLDING ( Czech Republic ), Bruker (US), Semilab ( Hungary …

Abeona Therapeutics

Abeona Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference | Globe Newswire | 5/28/2020

NEW YORK and CLEVELAND, May 28, 2020 (GLOBE NEWSWIRE) – Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that João Siffert, M.D., Chief Executive Officer, will present at … from the FDA and EMA for its pipeline candidates, including Regenerative Medicine Advanced Therapy designation for two candidates (EB-101 and ABO-102). www.abeonatherapeutics.com Investor Contact …

GlaxoSmithKline

Evox Therapeutics Appoints Martin Andrews as Non-Executive Director | PR Newswire | 5/27/2020

… with a strong track record of strategy development and operational delivery. He has had a long and successful career at GlaxoSmithKline, where he has held many senior positions. Most recently, Martin was Senior Vice President … held Board positions at Orchard Therapeutics and the Alliance for Regenerative Medicine. He is currently a Non-Executive Director of Freeline Therapeutics, where he brings his commercial expertise to their gene therapy portfolio of drugs …

Biogen

BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research | PR Newswire | 5/27/2020

… D, regulatory, strategy development, analytics and big data. Prior to her appointment at BrainStorm, Dr. Lindborg spent 8 years at Biogen Inc. the global biotech that discovers, develops and delivers worldwide innovative therapies for people … sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm …

Deerfield Management

Gene editing turns immune cells into more potent cancer killers | FierceBiotech | 6/15/2020

… by cytokines such as IL-15, said senior author Dan Kaufman, M.D., Ph.D., professor of medicine in the Division of Regenerative Medicine at the University of California, San Diego (UCSD), in a statement . The researchers … raised $114 million from the likes of Amgen Ventures and Deerfield Management to advance its pipeline of off-the-shelf NK cell therapies. Its lead candidate, NKX101, targets the cell surface receptor NKG2D and will …

Amgen Ventures

Gene editing turns immune cells into more potent cancer killers | FierceBiotech | 6/15/2020

… by cytokines such as IL-15, said senior author Dan Kaufman, M.D., Ph.D., professor of medicine in the Division of Regenerative Medicine at the University of California, San Diego (UCSD), in a statement . The researchers … Last September, Nkarta raised $114 million from the likes of Amgen Ventures and Deerfield Management to advance its pipeline of off-the-shelf NK cell therapies. Its lead candidate, NKX101, targets the cell surface receptor …

Smith & Nephew

COVID-19 Impact and Recovery Analysis- Regenerative Medicine Market 2020-2024 | Increasing Prevalence of Chronic Diseases to Boost Growth | Technavio | Business Wire | 6/4/2020

LONDON–(BUSINESS WIRE)–Jun 4, 2020– Technavio has been monitoring the regenerative medicine market and it is poised to grow by USD 9.55 billion during 2020-2024, progressing at a CAGR of over 20% during the … Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd., and Zimmer Biomet Holdings Inc. are some of the major market participants. The increasing prevalence of chronic diseases …

Bruker

$5.9 Billion Failure Analysis Market Outlook, 2025 - Implications of COVID-19, Trends & Developments, Key Players | PR Newswire | 5/28/2020

… in demand for failure analysis from the electronics & semiconductor industry, technological advancements in microscopes, and rising focus on nanotechnology and regenerative medicine. Energy Dispersive X-Ray Spectroscopy (EDX) technology expected to hold the largest share … Zeiss ( Germany ), JOEL, Ltd. ( Japan ), TESCAN OSRAY HOLDING ( Czech Republic ), Bruker (US), Semilab ( Hungary ), A&D Company, Ltd. ( Japan ), HORIBA, Ltd. ( Japan ), Leica Microsystems GmbH ( Germany ), Veeco Instruments (US), Oxford Instruments (UK), and Eurofins Scientific …

TPG Capital

ViaCyte Announces $27 Million Financing to Advance Next Generation Cell Therapies for Diabetes | PR Newswire | 5/26/2020

SAN DIEGO ViaCyte, Inc. , a privately held regenerative medicine company, today announced the close of an approximately $27 million private financing, part of the Series D preferred stock financing entered into in late 2018. Investors included, Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, and several individual supporters of the Company. Proceeds from the financing will be used to further advance the Company’s multi-product candidate approach …

Goldman Sachs

CRISPR Therapeutics to Participate in Upcoming Investor Conferences | Globe Newswire | 5/26/2020

… in the following investor conferences in June: Jefferies Global Healthcare Conference Date: Tuesday, June 2, 2020Fireside chat: 1:30 p.m. ET Goldman Sachs 41st Annual Global Healthcare Conference Date: Tuesday, June 9, 2020 Fireside chat: 9:40 … across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and …

Stryker

Tissue Engineering Market Size Worth $28.9 Billion by 2027 | CAGR: 14.2%: Grand View Research, Inc. | PR Newswire | 5/25/2020

… the Asia Pacific region throughout the forecast period Medtronic plc; Zimmer Biomet Holdings, Inc; Allergan plc; Athersys, Inc; ACell, Inc.; Stryker Corporation; Integra LifeSciences Corporation; and Baxter International, Inc. are the key players operating in … and-regeneration-industry Rapid advancements and a strong pipeline of regenerative medicine are anticipated to provide effective solutions for chronic conditions. Several companies in growing markets are striving to capitalize on the untapped market potential …

Daiichi Sankyo

Asia-Pacific CAR-T Pipeline Insights 2020 Featuring Over 50 CAR-T Therapy Companies in the Region | Globe Newswire | 5/15/2020

… Pacific CAR-T Pipeline” report has been added to ResearchAndMarkets.com’s offering. The Asia-Pacific CAR-T pipeline features over 50 regenerative medicine companies focusing on CAR-T in Asia. The report derives insights from in … Nanjing Legend Biotech, CARsgen Therapeutics, JW Therapeutics, AbClon, BiocurePharm, Eutilex, Daiichi Sankyo, Celgene, Otsuka and many more. Key Topics Covered …

Redmile Group

LifeSprout, Inc. Closes $28.5 Million Series A Financing | PR Newswire | 4/27/2020

BALTIMORE, Md. , April 27, LifeSprout, a privately-held regenerative medicine company founded with technology licensed from Johns Hopkins University , has closed a $28.5 million Series A financing. The company is using proceeds to support clinical development of novel therapeutic products from its Regenerative Matrix platform. The financing was led by Redmile Group, LLC, with new institutional investors Nexus Management, LP, Emerald Development Managers, LP, and the Abell Foundation joining the …

Needham & Company

Athersys Announces Closing of Public Offering of Common Stock | Yahoo News | 4/20/2020

… before deducting the underwriting discount and estimated offering expenses. BofA Securities acted as sole book-running manager for the offering. Needham & Company, SMBC and WBB Securities acted as co-managers for the offering. Athersys intends … indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization. Forward-Looking …

Flagship Pioneering

Cygnal Therapeutics Announces Scientific Advisory Board | PR Newswire | 1/31/2020

… Dr. Frenette has served as the director of the Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research at the Albert Einstein College of Medicine, Montefiore Health System in New … the company’s website at www.cygnaltx.com . About Cygnal Therapeutics Founded by Flagship Pioneering in 2017, Cygnal Therapeutics is the first company to build a platform to develop drugs in the new field of exoneural biology, an …

EW Healthcare Partners

Cognate BioServices closes Series B and completes acquisition of Cobra Biologics | PR Newswire | 1/22/2020

… Biologics, a leading CDMO specialized in providing development and manufacturing services for plasmid DNA and viral vector. Existing Cognate shareholder, EW Healthcare Partners and its co-investors led the investment in Cognate and the financing … and manufacturing solutions to the cell and gene immunotherapy and regenerative medicine industry around the world. Cobra Biologics has cGMP facilities in the UK and Sweden. Cognate operates an 80,000+ square foot manufacturing facility located …

Zacks Equity Research

3D Systems Joins CollPlant in Regenerative Medicine Efforts | Zacks | 1/14/2020

3D Systems Joins CollPlant in Regenerative Medicine Efforts Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article 3D Systems ( DDD - Free Report ) recently partnered with CollPlant Biotechnologies ( CLGN - Free Report ) to jointly develop tissue and scaffold bioprinting processes for third party companies, aiming to expedite the advancements in the biomedical …

Merrill Lynch

H.C. Wainwright Strengthens Its M&A and Advisory Capabilities | Business Wire | 1/13/2020

… a focus in healthcare and the life sciences, having worked in research and investment banking at Hambrecht & Quist, Cowen & Company, Merrill Lynch & Co. and T.R. Winston & Company. In addition, Mr. Meyers has served as a … T.R. Winston & Company. Mr. Jakimo is a Director of the Regenerative Medicine Foundation and The Cancer Trust, both not-for-profit organizations. He also serves on corporate advisory boards at the Columbia University Center for …

Innovation Fund

Promethera Attracts Sony Innovation Fund by IGV and Pegasus Tech Ventures as New Investors in Final Closing of Series D | PR Newswire | 12/16/2019

… today announced the addition of €7.5 million to its recent €39.7 million Series D financing led by new investors Sony Innovation Fund by IGV and Pegasus Tech Ventures. MEDIPAL Holdings, the family office Six Snow … the leading drug development organization in cell-based therapies and regenerative medicines targeting severe liver disorders.” Mr. Gen Tsuchikawa, CEO at Innovation Growth Ventures (IGV) added, “We decided to invest in Promethera due to the …

Pegasus Tech Ventures

Promethera Attracts Sony Innovation Fund by IGV and Pegasus Tech Ventures as New Investors in Final Closing of Series D | PR Newswire | 12/16/2019

… 7.5 million to its recent €39.7 million Series D financing led by new investors Sony Innovation Fund by IGV and Pegasus Tech Ventures. MEDIPAL Holdings, the family office Six Snow, a Japanese private investor and … the leading drug development organization in cell-based therapies and regenerative medicines targeting severe liver disorders.” Mr. Gen Tsuchikawa, CEO at Innovation Growth Ventures (IGV) added, “We decided to invest in Promethera due to the …

Alexandria Venture

Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson’s Disease | PR Newswire | 12/12/2019

SAN DIEGO , Dec. 12, Aspen Neuroscience, Inc. today announced its launch following a $6.5 million seed round — led by Domain Associates and Axon Ventures and including Alexandria Venture Investments, Arch Venture Partners, OrbiMed and Section 32 — to develop the first autologous cell therapies for Parkinson’s disease. Aspen’s proprietary approach was developed by the company’s co-founders, Jeanne F. Loring , Ph.D., Professor Emeritus and founding director of the Center for Regenerative …

Longitude Capital

Talaris Therapeutics to Present at American Society of Hematology (ASH) Annual Meeting | Business & Finance | manchestertimes.com | Business Wire | 12/6/2019

… can be restored in patients with certain immune-mediated or blood disorders. FCR001 has received both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration. A Phase … is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA and maintains corporate offices in Boston, MA and Louisville, KY. www.TalarisTx.com . View source version on businesswire.com : https://www.businesswire.com …

SVB Leerink

Organogenesis Holdings Inc. Announces Pricing of Public Offering of Class A Common Stock | Globe Newswire | 11/22/2019

CANTON, Mass., Nov. 21, Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today … to customary closing conditions. Credit Suisse Securities (USA) LLC and SVB Leerink LLC are acting as joint book-running managers of the offering and BTIG, LLC and Oppenheimer & Co. Inc. are acting as co-managers …

Apple Tree Partners

AVITA Medical Names David McIntyre as Chief Financial Officer | 11/18/2019

… Remains with Company as Chief Administrative Officer VALENCIA, Calif. & MELBOURNE, Australia–(BUSINESS WIRE)–AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic … entities. Most recently, Mr. McIntyre served as a Partner with Apple Tree Partners (ATP), a multibillion-dollar venture capture and growth equity fund focussed exclusively on life sciences. At ATP Mr. McIntyre was responsible for …

Casdin Capital

BioLife Solutions Announces Third Quarter 2019 Financial Results | PR Newswire | 11/12/2019

… Completed the acquisition of SAVSU Technologies, Inc. (“SAVSU”). Formed cell and gene therapy bioproduction innovation co-investment accelerator program with Casdin Capital and announced initial strategic investments in iVexSol and Sexton Biotechnologies. Successfully completed 19 … HypoThermosol ® shipping and storage media are highly valued in the regenerative medicine, biobanking and drug discovery markets. These biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation …

MPM Capital

Global Cell Encapsulation Research Report 2019-2030 | PR Newswire | 10/30/2019

… Bio ADIRA Aduro Biotech Advent Bioservices Agency for Science, Technology and Research AgenTus Therapeutics Aldagen Allele Biotechnology & Pharmaceuticals Alliance for Regenerative Medicine Allife Medical Science and Technology Allogene Therapeutics Alsace BioValley Altor BioScience ALTuCELL AlzeCure … Miltenyi Biotec Minovia Therapeutics Moderna Therapeutics MolecuVax MolMed Moraga Biotechnology MPM Capital Multimmune Mustang Bio Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering NantKwest National Cancer Institute National Center for Advancing Translational …

First Analysis

Anika Therapeutics Inc. (ANIK) CEO Joseph Darling on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 10/25/2019

Anika Therapeutics Inc. (NASDAQ: ANIK 5:00 Sylvia Cheung - CFO Joseph Darling - President & CEO Jim Sidoti - Sidoti & Company Joe Munda - First Analysis Brian Gagnon - Gagnon Securities Operator Good evening, ladies and gentlemen, and welcome to Anika … to deliver innovative products across the continuum of orthopedic and regenerative medicine therapies. As a testament to our team’s strong execution in the quarter, we successfully delivered double-digit revenue and earnings growth on the …

NCI

Efficient Methods to Prepare Hematopoietic Progenitor Cells in vitro for Therapeutic Use | National Institutes of Health | 9/18/2019

… erythrocytes, T cells, B cells, and natural killer cells. As such, they have high therapeutic potential in the fields of regenerative medicine and cancer immunotherapy, especially when generated from patient-derived induced pluripotent stem cells … expensive and not efficient. Researchers at the National Cancer Institute (NCI) developed a novel approach to produce HPCs from hiPSCs using a human mesenchymal stem cell (hMSC) 3D co-culture condition. hiPSCs and hMSCs are …

Morgan Stanley

Anika to Participate in the 2019 Morgan Stanley Global Healthcare Conference on September 10, 2019 | BioSpace | 9/4/2019

Anika to Participate in the 2019 Morgan Stanley Global Healthcare Conference on September 10, 2019 BEDFORD, Mass.–( BUSINESS WIRE )– Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology , today announced that Joseph Darling, President and Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer, will participate in a fireside chat at the 2019 Morgan Stanley

Harvard Medical School

Vizgen to Launch Early Release Program for Proprietary Spatial Genomics Technology | PR Newswire | 7/15/2020

… for high-resolution spatial biology,” said Dr. David R. Walt , Cofounder of Vizgen; Hansjörg Wyss Professor of Biologically Inspired Engineering, Harvard Medical School ; Professor of Pathology, Brigham and Women’s Hospital; Core Faculty, Wyss Institute for … medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, and regenerative medicine. For more information, go to www.vizgen.com , connect on social media @Twitter and @LinkedIn , and join the MERFISH Group at: https://bit.ly/merfishgroup . Contact …

University Medical Center

BrainStorm Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer’s Disease Program | PR Newswire | 7/8/2020

… international Phase 2 trial: Philip Scheltens , M.D., Ph.D., Professor of Cognitive Neurology and Director of the Alzheimer Centre at VU University Medical Center in Amsterdam, Netherlands ; and Bruno Dubois , M.D., Ph.D., Professor of Neurology at … sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm …

Cedars-Sinai Medical Center

BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS | PR Newswire | 7/2/2020

… later in 2020.” The Phase 3 NurOwn trial is being conducted at six centers of excellence: University of California, Irvine ; Cedars-Sinai Medical Center ; California Pacific Medical Center ; Massachusetts General Hospital ; University of Massachusetts Medical … sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm …

California Pacific Medical Center

BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS | PR Newswire | 7/2/2020

… Phase 3 NurOwn trial is being conducted at six centers of excellence: University of California, Irvine ; Cedars-Sinai Medical Center ; California Pacific Medical Center ; Massachusetts General Hospital ; University of Massachusetts Medical School and Mayo Clinic … sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm …

Boston Medical Center

Differentiation of Human Airway-Organoids From Induced Pluripotent Stem Cells (iPSCs) - PubMed | National Institutes of Health | 6/28/2020

doi: 10.1016/bs.mcb.2020.03.008. Epub 2020 Apr 25. Authors Ruobing Wang 1 , Katie B McCauley 2 , Darrell N Kotton 3 , Finn Hawkins 4 Affiliations 1 Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, United States; Division of Respiratory Diseases, Department of Medicine, Boston Children’s Hospital, Boston, MA, United States. 2 Respiratory Diseases, Novartis Institutes for BioMedical Research, Cambridge, MA, United States. 3 Center for Regenerative …

Boston Medical Center, Boston MA

Differentiation of Human Airway-Organoids From Induced Pluripotent Stem Cells (iPSCs) - PubMed | National Institutes of Health | 6/28/2020

doi: 10.1016/bs.mcb.2020.03.008. Epub 2020 Apr 25. Authors Ruobing Wang 1 , Katie B McCauley 2 , Darrell N Kotton 3 , Finn Hawkins 4 Affiliations 1 Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, United States; Division of Respiratory Diseases, Department of Medicine, Boston Children’s Hospital, Boston, MA, United States. 2 Respiratory Diseases, Novartis Institutes for BioMedical Research, Cambridge, MA, United States. 3 Center for Regenerative …

Mayo Clinic Health System

Mayo Clinic launches innovation exchange | Becker’s Hospital Review | 6/25/2020

… include virtual office hours with law firms as well as marketing and strategy consultants.Members will also receive targeted introductions to Mayo Clinic Health System experts. The exchange is currently taking applications.The health system also has … Ventures and director of business development in the Center for Regenerative Medicine at Mayo Clinic in Florida. Dr. Bruce has helped create five start-up companies and is a patent inventor on more than 160 …

Stanford Medicine

Immunotherapy shows potential in treating lung fibrosis | News Center | Stanford Medicine | 6/24/2020

… suggests that lung fibrosis develops when scar tissue cells escape immune surveillance, suggesting potential therapy. Jun 24 2020 Researchers at Stanford Medicine have shown that in idiopathic lung fibrosis, scar tissue cells spread by dodging … MD, at the Stanford Institute for Stem Cell Biology and Regenerative Medicine , has shown that scar tissue cells called fibroblasts are able to proliferate by avoiding immune surveillance, much like cancer cells. A therapy may …

Kaiser Permanente

Orca Bio Emerges With Nearly $300 Million to Transform Allogeneic Cell Therapy | Globe Newswire | 6/17/2020

… chip investors also participated in the latest round, including 8VC, DCVC Bio, ND Capital, Mubadala Investment Company, Kaiser Foundation Hospitals, Kaiser Permanente Group Trust and IMRF. The financing will support the continued advancement of Orca … Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine at Stanford University Ted Love, MD, Global Blood Therapeutics (GBT) Jonathan MacQuitty, PhD, Venture Partner at Lightspeed Venture Partners Joe Jimenez, Former Chief …

Massachusetts General Hospital

BrainStorm Announces that Pivotal Phase 3 Trial Remains on Track for Topline Data in Q4-2020 | PR Newswire | 6/2/2020

… the FDA. The clinical trial sites are at University of California, Irvine ; Cedars-Sinai Medical Center ; California Pacific Medical Center ; Massachusetts General Hospital ; University of Massachusetts Medical School and Mayo Clinic . Importantly, the trial’s primary … sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm …

Indiana University School of Medicine

Fact check: Early research shows fabric could neutralize coronaviruses | Yahoo News | 5/30/2020

Regenerative Medicine and Engineering at the Indiana University School of Medicine. While working at Ohio State University in 2017, he created an electrically based antimicrobial wound dressing that has been approved by the FDA and sold by Vomaris under the name Procella. Sen detailed the potential application to COVID-19 on May 14 in a preliminary study released online at the preprint server ChemRxiv. The site publishes early versions of …

Memorial Hospital, Chester IL

Update on Talaris’ Phase 2 Study of FCR001 in Living Donor Kidney Transplant Recipients to be Presented at ATC Virtual Congress | Business & Finance | manchestertimes.com | Business Wire | 5/29/2020

… of surgery in organ transplantation at Northwestern University Medical School, director of the living donor renal transplant program at Northwestern Memorial Hospital and lead investigator for the trial. The following are specific details regarding the … blood disorders. FCR001 has received both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration. A Phase 3 trial of FCR001 in living donor kidney transplant recipients …

Wake Forest Baptist Health

The most exciting opportunities in spine today from 11 surgeons | Beckers Spine Review | 5/27/2020

… as their practices change due to the pandemic. Charles Branch Jr., MD. Executive Director of the Spine Service Line at Wake Forest Baptist Health System (Winston-Salem, N.C.): I believe the most intriguing opportunity involves … Perez-Cruet, MD. Beaumont Hospital (Royal Oak, Mich.): Opportunities in regenerative medicine and advances in minimally invasive spine surgery. We are also excited about showing our outcomes in MIS surgery via the Michigan Spine Surgery …

Mount Sinai Hospital

The most exciting opportunities in spine today from 11 surgeons | Beckers Spine Review | 5/27/2020

… surgery in the case of severe radiculopathy, myelopathy or spine related pain. Andrew Hecht, MD. Chief of Spine Surgery at Mount Sinai Hospital and Mount Sinai Health System (New York City): One of the positive … Perez-Cruet, MD. Beaumont Hospital (Royal Oak, Mich.): Opportunities in regenerative medicine and advances in minimally invasive spine surgery. We are also excited about showing our outcomes in MIS surgery via the Michigan Spine Surgery …

Meridian Health

Hackensack Meridian Health Invests in EpiBone, Inc., A Regenerative Medicine Company | PR Newswire | 5/19/2020

EDISON, N.J. Hackensack Meridian Health has invested in EpiBone, Inc., a biotechnology company targeting the growth of personalized bone and cartilage grafts using stem cell technologies and 3D imaging and designs. This investment in a clinical-stage regenerative medicine company is Hackensack Meridian Health ‘s fourth through the Bear’s Den, the health network’s successful innovation program. (PRNewsfoto/Hackensack Meridian Health) “Our industry is going to be transformed by how we …

Hackensack Meridian

Hackensack Meridian Health Invests in EpiBone, Inc., A Regenerative Medicine Company | PR Newswire | 5/19/2020

EDISON, N.J. Hackensack Meridian Health has invested in EpiBone, Inc., a biotechnology company targeting the growth of personalized bone and cartilage grafts using stem cell technologies and 3D imaging and designs. This investment in a clinical-stage regenerative medicine company is Hackensack Meridian Health ‘s fourth through the Bear’s Den, the health network’s successful innovation program. (PRNewsfoto/Hackensack Meridian Health) “Our industry is going to be transformed by how we …

Medical Center

Ultragenyx Announces Positive Data from Confirmatory Cohort of Phase 1/2 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) | Globe Newswire | 5/15/2020

… glycogen storage disease type Ia,” said David Weinstein, M.D., M.M.Sc., Professor and Director, Glycogen Storage Disease Program at Connecticut Children’s Medical Center and UConn Health. “The third cohort of patients is experiencing more rapid improvement … Drug Designation in both the United States and Europe, and Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation in the United States. About Ultragenyx Ultragenyx is a biopharmaceutical company committed to bringing to …

UPMC

ALung Announces Commercial Development of its Breakthrough Next Generation Artificial Lung | Business Wire | 5/5/2020

… Pittsburgh. Developed by Professor William Federspiel, PhD and colleagues at the Swanson School of Engineering and the McGowan Institute for Regenerative Medicine, this new technology platform significantly enhances gas exchange efficiency while reducing the deleterious … or supplement to mechanical ventilation. ALung is backed by Philips, UPMC Enterprises, Abiomed, The Accelerator Fund, Allos Ventures, Birchmere Ventures, Blue Tree Ventures, Eagle Ventures, Riverfront Ventures, West Capital Advisors, and other individual investors. For …

University Hospital

Athersys and University Hospitals Cleveland Medical Center Announce Activation of the First Clinical Site for the MACOVIA Study, a Pivotal Phase 2/3 Study Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS | Business Wire | 5/1/2020

CLEVELAND–(BUSINESS WIRE)–May 1, 2020– Athersys, Inc. (NASDAQ: ATHX) and University Hospitals Cleveland Medical Center (UH Cleveland) announced today that UH Cleveland is now open as the first clinical site for the MACOVIA (MultiStem … tremendous achievement,” commented Dr. Anthony Ting, PhD, Vice President of Regenerative Medicine and Head of Cardiopulmonary Programs at Athersys. “This was only possible due to the diligent effort performed by UH Cleveland and its dedicated …

Baylor College of Medicine

Several Potential Coronavirus Vaccines and Treatments Progressing Towards Human Trials | PR Newswire | 4/13/2020

… pandemic,” said Dr. Peter Hotez , who is a co-director of the Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine. Active biotech and pharma companies in the markets this week include … biotech industry include: Pluristem Therapeutics Inc. (NASDAQ: PSTI ) a leading regenerative medicine company developing a platform of novel biological therapeutic products, recently announced preliminary data from its compassionate use program, treating seven patients suffering from …

Children's Hospital

Capricor Therapeutics to Host Key Opinion Leader Call on Cardiac Complications of Duchenne Muscular Dystrophy Nasdaq:CAPR | Globe Newswire | 4/13/2020

… at 1:30 pm Eastern Time. The call will feature a presentation by key opinion leader Michael Taylor, M.D., Ph.D. (Cincinnati Children’s Hospital), Director of Advanced Imaging Innovation. Dr. Taylor will provide an overview of Duchenne … as possible.” The FDA has granted Capricor’s CAP-1002 RMAT (Regenerative Medicine Advanced Therapy), Orphan Drug, and Rare Pediatric Disease designations. Conference Call Details Wednesday, April 15 th @ 1:30pm Eastern Time Domestic 877-705-6003 International: 201-493-6725 …

Sanford Health

FDA-Approved Randomized Controlled Feasibility Study Finds InGeneron’s Regenerative Cell Therapy to Significantly Reduce Pain and Improve Shoulder Function Over Corticosteroid Injection to Address Symptomatic Partial-Thickness Rotator Cuff Tears | 4/7/2020

… UA-ADRCs) are now available in the Journal of Orthopaedic Surgery and Research . This prospective multicenter feasibility study performed by Sanford Health is the first randomized controlled trial in which cells isolated from patients’ own … stage cell therapy company enabling novel, safe and evidence-based regenerative medicine therapies. Our purpose is to set new therapeutic standards by developing treatments that unlock the healing potential of each patient’s own regenerative cells …

Mayo Clinic

Monarch Biosciences Closes Seed Round Financing | Globe Newswire | 4/6/2020

… completed preclinical animal and human simulator testing conducted by a team headed by David Kallmes, M.D., Professor of Radiology, at Mayo Clinic’s campus in Rochester, Minnesota. “We welcome Checkmate Capital’s investment,” said MonarchBio’s CEO, Leon … biomaterial platform for use in advanced medical device, biotechnology, and regenerative medicine products. TFN is fabricated using techniques adapted from the electronics industry. An ultra-pure film of Nitinol, 1-20 micrometers thick (for comparison, the …

Wake Forest Baptist Medical Center

RECELL® System Data Accepted to 52nd Annual American Burn Association Meeting Available Online | Business Wire | 4/2/2020

VALENCIA, Calif. & MELBOURNE, Australia- AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today the availability of RECELL … Impact of ASCS Adoption v James H. Holmes, IV, MD Wake Forest Baptist Medical Center 558 Relationship Between Patient Characteristics and Number of Procedures as well as Length of Stay for Patients Surviving Severe Burn …

Baptist Medical Center

RECELL® System Data Accepted to 52nd Annual American Burn Association Meeting Available Online | Business Wire | 4/2/2020

VALENCIA, Calif. & MELBOURNE, Australia- AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today the availability of RECELL … ASCS Adoption v James H. Holmes, IV, MD Wake Forest Baptist Medical Center 558 Relationship Between Patient Characteristics and Number of Procedures as well as Length of Stay for Patients Surviving Severe Burn Injuries: Analysis …

Healthspan

Houston Healthspan Innovation Group Launches to Transform Regenerative Medicine Research and Development | Benzinga | 9/24/2019

HOUSTON , Sept. 24, 2019 /PRNewswire/ – Houston Healthspan Innovation Group is a new accelerator for early stage life sciences and biotech companies focused on the research, development and commercialization of new therapies and technologies in the expanding field of regenerative medicine. The brainchild of CEO and Founder Dr. Ed Bosarge , a pioneer in advancing leading-edge life sciences projects, Houston Healthspan will offer start-up companies and joint-venture partners access …

Houston Healthspan Innovation Group Launches to Transform Regenerative Medicine Research and Development | 9/24/2019

HOUSTON , Sept. 24, 2019 /PRNewswire/ – Houston Healthspan Innovation Group is a new accelerator for early stage life sciences and biotech companies focused on the research, development and commercialization of new therapies and technologies in the expanding field of regenerative medicine

Steve Aoki

eSmartr, Steve Aoki Partner on a Line of Cognitive Boosting Smart Compression Sleeves | PR Newswire | 7/16/2020

Designed to Naturally Improve Mindfulness MISSISSAUGA, ON , July 16, 2020 /PRNewswire/ - Two-time Grammy-nominated DJ/Producer Steve Aoki and eSmartr partner to launch a limited-edition line of Smart Compression Sleeves that improve brain … FOUNDATION, supports organizations in brain science research that focuses on regenerative medicine and brain preservation. SOURCE eSmartr …

Mike Perry

AVITA Therapeutics Provides Company Update and Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2020 | Business Wire | 7/9/2020

VALENCIA, Calif. & MELBOURNE, Australia- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs … with the onset of the COVID-19 pandemic,” said Dr. Mike Perry, AVITA Therapeutics’ Chief Executive Officer. “Like many others, this quarter we witnessed the most challenging commercial conditions since the RECELL System was launched …

Brian M. Culley

Lineage Cell Therapeutics Announces Extension of OpRegen® Development Grant From Israel Innovation Authority | Business & Finance | manchestertimes.com | Business Wire | 7/6/2020

… financial support based on the positive momentum and clinical achievements we have demonstrated with our OpRegen program to date,” stated Brian M. Culley, Lineage CEO. “We continue to generate promising data supporting the use of … with notable institutions like the IIA, the California Institute for Regenerative Medicine , and Cancer Research UK , provide not only capital, but also external validation of our programs, and we are working to strengthen and expand …

Geoff MacKay

AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials | Business & Finance | heraldchronicle.com | Business Wire | 7/6/2020

… 1 leads to an array of serious symptoms and the current standard of care does not halt disease progression,” said Geoff MacKay, AVROBIO’s president and CEO. “With a single dose of our investigational lentiviral gene … part by grants to UCSD from the California Institute for Regenerative Medicine (CIRM), Cystinosis Research Foundation (CRF) and National Institutes of Health (NIH). View source version on businesswire.com : https://www.businesswire.com/news/home/20200706005091/en/ CONTACT …

Chaim Lebovits

BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS | PR Newswire | 7/2/2020

… a step closer to potentially filing a Biologics License Application to make MSC-NTF cells available to people with ALS,” Chaim Lebovits , CEO of BrainStorm stated. “I would like to thank the investigators and their … sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm …

Charles E. Schmidt

FAU Poll Finds Climate Change Still Is Important Topic For Floridians In Era Of Coronavirus | PR Newswire | 6/30/2020

… signal a similar change in coming years for the GOP across the nation,” Polsky said. CES is part of FAU’s Charles E. Schmidt College of Science , while BEPI is in FAU’s College of Business . The … strategic plan: Healthy aging, biotech, coastal and marine issues, neuroscience, regenerative medicine, informatics, lifespan and the environment. These areas provide opportunities for faculty and students to build upon FAU’s existing strengths in research and scholarship …

James L. Sherley

Asymmetrex’s Plan for Free Stem Cell Counting Is The Feature Story by Superb Crew News | PRWeb | 6/23/2020

… BOSTON In its June 22 online post, business and technology news platform Superb Crew reported its feature interview with Dr. James L. Sherley, M.D., Ph.D., founder and director of stem cell biotechnology company Asymmetrex . Superb … of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease …

Robin Smith

Orig3n Announces Comprehensive Solution To Provide COVID-19 Testing For Boarding Schools | PR Newswire | 6/23/2020

… COVID19 testing nation-wide. Since its inception in 2014, Orig3n has built the largest suite of direct-to-consumer genetic tests on the market, and the world’s most comprehensive cell bank for commercial regenerative medicine applications. For more information, visit www.orig3n.com . SOURCE Orig3n Inc. Related Links http://www.orig3n.com …

Christine E. Lynn

FAU Now Offers COVID-19 Contact Tracing And Risk-Reduction Public Health Certificate | PR Newswire | 6/17/2020

… In response to the high demand for one of the fastest-growing jobs in the U.S., Florida Atlantic University ‘s Christine E. Lynn College of Nursing has launched a new, online public health certificate course … strategic plan: Healthy aging, biotech, coastal and marine issues, neuroscience, regenerative medicine, informatics, lifespan and the environment. These areas provide opportunities for faculty and students to build upon FAU’s existing strengths in research and scholarship …

Corey Orava

Enso Discoveries, LLC is Excited to Announce the Launch of a Human Health Division–Enso Doctors–Led by Newly Appointed VP of Human Health, Jim Long, MT (ASCP) | PRWeb | 6/16/2020

… regenerative medicine, led by Chief Scientific Officer, Dr. Corey Orava – a regenerative medicine expert – along with our consulting pathologist and excellent university relationships. We design, patent and validate all of our own unique products. “We knew our kits would be great for physicians. Judging by the success we have seen and heard from the current group of physicians using our products we know we can add great value to those …

Patrick Farley

Enso Discoveries, LLC is Excited to Announce the Launch of a Human Health Division–Enso Doctors–Led by Newly Appointed VP of Human Health, Jim Long, MT (ASCP) | PRWeb | 6/16/2020

… to afford to participate with this promising regenerative therapy. Enso Doctors utilizes the extensive experience Enso Discoveries, LLC has in regenerative medicine, led by Chief Scientific Officer, Dr. Corey Orava – a regenerative medicine expert – along … improve their service offerings,” explains CEO of Enso Discoveries, LLC, Patrick Farley. “I’ve used many other kits with an average price of a PRP kit, with any volume, approaching $180-$250 each and an investment …

David McIntyre

AVITA Medical Limited Proposed Redomiciliation to the United States of America - Chair’s Address to Scheme Meeting | Business Wire | 6/15/2020

… is unable to be present today and sends his apologies. We are also joined by the Company’s Chief Financial Officer, David McIntyre, and our Company Secretary, Mr Mark Licciardo. Representatives are also present from: our … Webcast ends] ABOUT AVITA MEDICAL LIMITED AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and proprietary …

Steven Romano

Mallinckrodt to Present Phase 3 StrataGraft® Regenerative Skin Tissue Clinical Trial Results on Severe Burns During the Virtual American Burn Association 52nd Annual Meeting | PR Newswire | 6/15/2020

… as well as data that provides insights into the implications of autografting during this year’s virtual ABA Annual Meeting,” said Steven Romano , M.D., Executive Vice President and Chief Scientific Officer at Mallinckrodt . “At Mallinckrodt, we … among the first products designated by the Agency as a Regenerative Medicine Advanced Therapy (RMAT) under the provisions of the 21st Century Cures Act. Funding and technical support for the continued development of StrataGraft skin …

David Davidson

New Data Show Near Elimination of Sickle Cell Disease-Related Vaso-Occlusive Crises and Acute Chest Syndrome in Phase 1/2 Clinical Study of bluebird bio’s LentiGlobin™ Gene Therapy for Sickle Cell Disease at 25th EHA Congress | Business Wire | 6/12/2020

… this study is impressive and demonstrates the potential of LentiGlobin for SCD as a treatment for this serious disease,” said David Davidson, M.D., chief medical officer, bluebird bio. “These results illustrate the type of outcomes … treatment of SCD. The U.S. FDA granted orphan drug designation, regenerative medicine advanced therapy (RMAT) designation and rare pediatric disease designation for LentiGlobin for SCD. LentiGlobin for SCD is investigational and has not been approved …

Kevin Richardson

SANUWAVE Health Enters Into Exclusive Letter of Intent to Acquire Celularity’s UltraMIST® and Exclusive Partnership Rights for Wound Care Biologic Products | Globe Newswire | 6/10/2020

… profile. “UltraMIST® and the Celularity wound care biologic products, Biovance® and Interyl®, are excellent complements to our dermaPACE® System,” said Kevin Richardson, SANUWAVE Chief Executive Officer. “The contemplated acquisition would bolster our advance wound care … of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing …

Kevin Richard

SANUWAVE Health Enters Into Exclusive Letter of Intent to Acquire Celularity’s UltraMIST® and Exclusive Partnership Rights for Wound Care Biologic Products | Globe Newswire | 6/10/2020

… profile. “UltraMIST® and the Celularity wound care biologic products, Biovance® and Interyl®, are excellent complements to our dermaPACE® System,” said Kevin Richardson, SANUWAVE Chief Executive Officer. “The contemplated acquisition would bolster our advance wound care … of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing …

Anthony Atala

MSC Therapy for Acute Respiratory Distress Syndrome; It’s Time to Accelerate Clinical Trials for COVID-19 Patients in Need | PR Newswire | 6/3/2020

Anthony Atala , MD, Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. “Having additional potential therapies, such as MSCs, could be highly beneficial to patients with COVID-19.” To date, the FDA has approved more than a dozen investigational new drug applications for the use of MSCs for COVID-19-related conditions. The National Institutes of Health (NIH) has also supported …

Ralph Kern

BrainStorm to Participate in BIO Digital 2020 | PR Newswire | 6/3/2020

… BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Dr. Ralph Kern , M.D, President and Chief Medical Officer will present a corporate overview during the … sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm …

Michael May

Toronto centre solving cell manufacturing challenges to benefit patients and global industry | Globe Newswire | 6/2/2020

… renew collaboration agreement for Centre for Advanced Therapeutic Cell Technologies June 02, 2020 06:00 ET Source: Centre for Commercialization of Regenerative Medicine (CCRM) TORONTO and MARLBOROUGH, Mass., June 02, 2020 (GLOBE NEWSWIRE) – With Health Canada … the-art equipment and a spirit of innovation meet,” says Michael May, President and CEO of CCRM. “Continuing to partner in the operation of CATCT will enable us to move the cell and gene therapy …

Mark Enyedy

ImmunoGen Appoints Stacy Coen as Senior Vice President and Chief Business Officer - Business Wire | 6/1/2020

… the ImmunoGen leadership team as mirvetuximab soravtansine moves through registration studies and our early-stage pipeline continues to advance,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer. “Stacy is a proven business leader with … and is a member of MassBio and the Alliance for Regenerative Medicine (ARM). Ms. Coen received a BS in Finance and Economics from the University of Massachusetts and an MBA from the Darden Graduate School …

Carl Zeiss

$5.9 Billion Failure Analysis Market Outlook, 2025 - Implications of COVID-19, Trends & Developments, Key Players | PR Newswire | 5/28/2020

… in demand for failure analysis from the electronics & semiconductor industry, technological advancements in microscopes, and rising focus on nanotechnology and regenerative medicine. Energy Dispersive X-Ray Spectroscopy (EDX) technology expected to hold the largest share … Thermo Fisher Scientific, Inc. (US), Hitachi High-Technologies Corporation ( Japan ), Carl Zeiss ( Germany ), JOEL, Ltd. ( Japan ), TESCAN OSRAY HOLDING ( Czech Republic ), Bruker (US), Semilab ( Hungary ), A&D Company, Ltd. ( Japan ), HORIBA, Ltd. ( Japan ), Leica Microsystems …

Yehiel Tal

CollPlant Biotechnologies Reports First Quarter (Q1) 2020 Financial Results | PR Newswire | 5/27/2020

… for 3D bioprint lung scaffolds, all despite the inherent challenges stemming from the rapid global spread of COVID-19,” stated Yehiel Tal , the Chief Executive Officer of CollPlant. “We implemented remote working and workplace protocols … States of America (“U.S. GAAP”). About CollPlant CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. Our products are based on our rhCollagen (recombinant human collagen) that …

Silviu Itescu

Mesoblast Reports Strong Financial Position and Substantial Operational Progress For the Period Ended March 31, 2020 Australian Stock Exchange:MSB.AX | Globe Newswire | 5/27/2020

… million (A$235 million) after adjusting for a US$90 million (A$138 million) capital raise. Mesoblast Chief Executive Dr Silviu Itescu stated: “This past quarter has underscored the value of our lead product candidate … product is being developed for these patients under existing FDA Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designations. MPC-06-ID for Chronic Low Back Pain Final study visits for all patients have been …

Fred Grossman

Clinical Outcomes Using RYONCIL™ (remestemcel-L) in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three Articles in Biology of Blood and Marrow Transplantation | Globe Newswire | 5/25/2020

… and Marrow Transplantation, the official publication of the American Society for Transplantation and Cellular Therapy. Mesoblast Chief Medical Officer Dr Fred Grossman said: “Results from these three trials show a consistent pattern of safety and … Professor and Assistant Dean of Medicine at the Stem Cell & Regenerative Medicine Center at the University of Wisconsin–Madison and Chair of the International Society of Cell and Gene Therapy (ISCT) MSC Committee, concluded that …

Shai Yarkoni

Cellect Biotechnology Reports First Quarter 2020 Financial and Operating Results; Continues to Demonstrate Significant Progress Despite Adjusted Operations Due to COVID-19 | PR Newswire | 5/21/2020

… recruitment of the final patient in the Israel trial, we remain bullish on Cellect’s long-term business prospects,” commented Dr. Shai Yarkoni , Chief Executive Officer. “In addition to these clinical opportunities, we are making considerable … treatments and procedures in a wide variety of applications in regenerative medicine. The Company’s current clinical trial is aimed at bone marrow transplantations in cancer treatment. Forward Looking Statements This press release contains forward-looking …